This document provides an update on the safety of substances of human origin (SoHO) in relation to COVID-19. It reassesses the risk and proposes revised mitigation measures for preventing transmission through SoHO.
This reporting protocol is intended for reporting national case-based data for surveillance of hepatitis of unknown origin from all the countries and areas of the WHO European Region, including the 27 countries of the European Union (EU) and the additional three countries of the European Economic Area (EEA), to the European level.
This document provides guidance on diagnostic testing, molecular characterisation and metagenomic analysis for suspect cases of severe acute hepatitis of unknown aetiology.
This document aims to help public health authorities in EU/EEA countries and the UK in their tracing and
management of persons, including healthcare workers, who have had contact with COVID-19 cases.
This document aims to provide guidance to EU/EEA healthcare facilities and healthcare providers on infection prevention and control (IPC) measures for the management of suspected and confirmed cases of COVID-19 infection in healthcare settings, including long-term care facilities. It also offers guidance on the management of specimens at laboratories in the EU/EEA.
Urgent action is required to improve efforts to prevent hepatitis B and C infections in the EU/EEA and the UK if the region is to meet the 2020 targets for the elimination of viral hepatitis as a serious threat to public health. Significant gaps in the reported data in relation to prevalence and prevention of HBV and HCV in EU/EEA and the UK present a major challenge to monitoring progress towards the targets for elimination of hepatitis.
This document provides guidance on infection prevention and control (IPC) measures to healthcare providers in the European Union/European Economic Area (EU/EEA) and the United Kingdom (UK) in order to prevent COVID-19 infection.
The aim of this document is to describe COVID-19 clusters and outbreaks in the EU/EEA and the UK linked to occupational settings, including healthcare and non-healthcare settings, and to identify possible factors contributing to transmission in these settings.